Graves' Disease - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for graves’ disease including molecules at pre-clinical and discovery stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, by territory, therapeutic modality, and target.

Overview of the drug development pipeline for graves’ disease  

Graves’ disease is an autoimmune disorder that causes the thyroid gland to produce excess thyroid hormone in the body. Factors such as inheritance from either parent or any other autoimmune disorders are consequent in the occurrence of this disease. Also, unknown infection or emotional/physical stress increase the incidence of graves’ disease. This disorder gives rise to symptoms such as Goitre, weight loss, frequent bowel movements, trouble getting pregnant, and hair thinning. Technavio’s market research analysts outlines that this disorder can be treated with therapeutics such as medication, radioiodine therapy, and thyroid surgery. Companies in the pharmaceutical industry are investing steadily in drug development activities.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the discovery drug development stage. Our market research analysts have also identified that almost same amount of drug molecules are under the phase I/II and pre-clinical drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the phase I stage. 

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of graves’ disease. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• Novartis
• Evofem Biosciences
• Thyritope Biosciences

Therapeutic assessment of the drug development pipeline for graves’ disease by route of administration

• Intradermal
• Intramuscular
• Intravenous

The intradermal route of administration (ROA) involves the administration of drug substances within the layers of the skin. It has been observed that the two of total therapeutics for graves’ diseases are being developed for intradermal administration.

Therapeutic assessment of the drug development pipeline for graves’ disease by therapeutic modality

• Peptide
• Monoclonal antibody
• Small molecule

According to this pipeline analysis report, majority of the molecules that are currently in the drug development pipeline for graves’ disease are being developed as peptides. Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. The reaction of carboxyl group of one amino acid with another amino acid group is consequent in the formation of covalent chemical bonds.  

Technavio also offers customization on reports based on specific client requirement.